10-QPeriod: Q2 FY2026

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2026

Filed July 30, 2026For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) has filed its 10-Q for the period ending July 30, 2026. This report provides investors with a crucial update on the company's financial performance and operational status during the second quarter. While the detailed financial statements and management's discussion offer a comprehensive view, preliminary analysis suggests a focus on key performance indicators, strategic initiatives, and forward-looking statements that will shape investor sentiment. Investors should pay close attention to revenue drivers, pipeline developments, and any significant legal or risk factor updates presented in the filing. The management's discussion and analysis (MD&A) section is particularly important for understanding the company's performance trends, liquidity, and capital resources. It will likely elaborate on the factors contributing to the reported earnings and comprehensive income, as well as any challenges or opportunities the company is navigating. Investors should also review the notes to the consolidated financial statements for detailed accounting policies and significant transactions that may impact the company's financial health and future outlook. The inclusion of quantitative and qualitative disclosures on market risk and details on legal proceedings further offer insights into potential volatilities and contingent liabilities.

Key Highlights

  • 1The filing includes the Consolidated Statements of Earnings and Comprehensive Income/(Loss), Consolidated Balance Sheets, and Consolidated Statements of Cash Flows for the period.
  • 2Management's Discussion and Analysis of Financial Condition and Results of Operations provides detailed insights into the company's performance and outlook.
  • 3Key updates on legal proceedings, risk factors, and unregistered sales of equity securities are presented.
  • 4The report details quantitative and qualitative disclosures about market risk, informing investors of potential financial exposures.
  • 5Notes to Consolidated Financial Statements offer critical details on accounting policies and significant financial events.
  • 6The filing outlines 'Other Information' and includes a comprehensive list of exhibits.

Frequently Asked Questions

The 10-Q filing contains the Consolidated Statements of Earnings and Comprehensive Income/(Loss), Consolidated Balance Sheets, and Consolidated Statements of Cash Flows. Investors should refer to these statements for detailed financial performance metrics, including revenue, net income, earnings per share, assets, liabilities, and cash flow activities. The MD&A section will provide further analysis and context for these results.

Item 1A, 'Risk Factors,' in the 10-Q filing will outline the significant risks and uncertainties that could materially affect the company's business, financial condition, or results of operations. Investors should carefully review this section for information on competitive landscape, regulatory changes, patent expirations, pipeline success, and other operational or market-related risks.

Yes, Item 1, 'Legal Proceedings,' details any significant ongoing lawsuits or legal disputes that Bristol Myers Squibb is involved in. This section is crucial for understanding potential financial liabilities or impacts on the company's operations arising from legal matters.

The 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' section (Item 2) and the Consolidated Statements of Cash Flows will provide comprehensive information on Bristol Myers Squibb's liquidity, cash flow generation, and capital resources. Investors should analyze how the company manages its cash, debt, and investments to support its operations and growth strategies.